Apigenin is a naturally occurring flavonoid compound found abundantly in chamomile, parsley, celery, and other fruits and vegetables. It works through multiple mechanisms including modulating GABAergic neurotransmission, reducing inflammation via NF-κB pathway inhibition, and exhibiting antioxidant properties. Primarily studied for its anxiolytic, sleep-promoting, anti-inflammatory, and potential anti-cancer effects.

Overview

Apigenin (4',5,7-trihydroxyflavone) is a plant-derived flavonoid belonging to the flavone subclass, with the molecular formula C₁₅H₁₀O₅. It is widely distributed in fruits, vegetables, and herbs, with particularly high concentrations in chamomile flowers (where it constitutes approximately 68% of total flavonoids), parsley (215 mg per 100 g), and celery (19 mg per 100 g). Apigenin has attracted considerable research interest due to its broad spectrum of biological activities spanning anti-inflammatory, antioxidant, anticancer, neuroprotective, and anxiolytic effects.

At the molecular level, apigenin modulates numerous signaling pathways and cellular targets. It suppresses inflammation through inhibition of pro-inflammatory cytokines and the NF-κB pathway, and acts as a free radical scavenger to reduce oxidative stress. Notably, apigenin binds competitively to the benzodiazepine site on GABA-A receptors, which underlies its calming and mildly sedative effects — a property that has made chamomile tea a traditional remedy for relaxation and sleep. In cancer research, apigenin has demonstrated the ability to induce apoptosis, arrest cell cycle progression, inhibit angiogenesis, and suppress cancer cell migration across multiple tumor types in preclinical models.

Apigenin also shows promise in neuroprotection, having improved memory and learning deficits in Alzheimer's disease mouse models through its antioxidant and anti-inflammatory actions. It can modulate estrogen signaling to promote neurogenesis and inhibit HDAC enzymes implicated in tumor proliferation. Despite extensive preclinical evidence, clinical translation remains limited by apigenin's low aqueous solubility and bioavailability, though novel delivery systems including nanoformulations are being developed to address these challenges. Typical supplemental doses range from 50 to 400 mg daily.

Mechanism of Action

Flavonoid Structure & Multi-Target Activity

Apigenin (4',5,7-trihydroxyflavone) is a flavone found abundantly in chamomile, parsley, and celery. Its planar structure and hydroxyl group arrangement enable interactions with numerous protein targets, making it a pleiotropic bioactive compound with anti-inflammatory, anxiolytic, and chemopreventive properties (PMID: 23159424).

GABAergic & Anxiolytic Mechanism

Apigenin binds to the benzodiazepine site on GABA_A receptors as a positive allosteric modulator, enhancing chloride ion conductance and neuronal inhibition. Unlike classical benzodiazepines, apigenin shows partial agonist activity with lower sedation liability. It also inhibits monoamine oxidase (MAO) activity, modulating serotonin and norepinephrine levels in anxiety-related circuits (PMID: 10617998).

CD38 Inhibition & NAD+ Metabolism

Apigenin is a potent inhibitor of CD38, the primary NADase enzyme responsible for age-related NAD+ decline. By blocking CD38's hydrolytic activity, apigenin preserves intracellular NAD+ pools, supporting sirtuin activity (SIRT1/SIRT3), mitochondrial function, and cellular energy metabolism. This mechanism has significant implications for aging and metabolic health (PMID: 23636399).

Anti-Inflammatory Pathways

Apigenin suppresses NF-kB activation by inhibiting IKK phosphorylation and blocks MAPK/ERK signaling. It also inhibits COX-2 expression and prostaglandin E2 production. Through inhibition of the NLRP3 inflammasome, apigenin reduces IL-1beta and IL-18 secretion, attenuating both acute and chronic inflammatory responses (PMID: 25656742).

Cell Cycle & Apoptotic Regulation

Apigenin induces G2/M cell cycle arrest by inhibiting cyclin B1/CDK1 and activates the intrinsic apoptotic pathway through p53 stabilization, Bax upregulation, and cytochrome c release. It also inhibits PI3K/Akt/mTOR signaling and HIF-1alpha expression, suppressing angiogenesis and tumor cell survival.

Reconstitution Calculator

Research

Safety Profile

Common Side Effects

• Generally well-tolerated at dietary and moderate supplemental doses
• Mild sedation and drowsiness (apigenin has GABAergic and anxiolytic activity)
• Contact dermatitis when applied topically (especially from chamomile-derived sources)
• GI upset at high supplemental doses

Serious Concerns

• Estrogenic/anti-estrogenic activity: Apigenin binds estrogen receptors and exhibits complex hormonal modulation. It may act as an aromatase inhibitor at higher concentrations. Implications for hormone-sensitive cancers (breast, ovarian, endometrial) are not fully characterized — could be protective or harmful depending on context.
• CYP enzyme inhibition: Apigenin is a potent inhibitor of CYP2C9 in vitro. At high supplemental doses, this could alter the metabolism of narrow therapeutic index drugs.
• Bleeding risk: In vitro antiplatelet effects noted; clinical significance at supplemental doses is uncertain but warrants caution.
• No standardized pharmaceutical-grade formulations exist; bioavailability is low and highly variable between products.

Contraindications

• Known allergy to chamomile or plants in the Asteraceae/Compositae family
• Hormone-sensitive conditions (use with caution; discuss with oncologist)
• Pregnancy (insufficient safety data; some animal studies suggest developmental effects)
• Breastfeeding (insufficient data)

Drug Interactions

• CYP2C9 substrates (warfarin, phenytoin, NSAIDs): Apigenin may increase drug levels by inhibiting CYP2C9
• CYP1A2 substrates (theophylline, caffeine, clozapine): Potential inhibition at high doses
• Benzodiazepines and sedatives: Additive CNS depression due to GABAergic activity
• Anticoagulants/antiplatelets: Theoretical additive bleeding risk
• Hormonal therapies (tamoxifen, aromatase inhibitors, HRT): Complex estrogen receptor interactions; may alter efficacy
• CD45 phosphatase modulation: May affect immune cell signaling; clinical implications unknown

Special Populations

• Pediatric: Safe at dietary levels (chamomile tea); supplemental doses not studied
• Geriatric: Sedation risk; beneficial anxiolytic effects possible at moderate doses
• Hepatic impairment: CYP inhibition concerns amplified; use with caution

Monitoring

• INR monitoring if co-administered with warfarin or other CYP2C9 substrates
• Sedation assessment, particularly in elderly or polypharmacy patients
• Hormone levels in patients with hormone-sensitive conditions
• No routine laboratory monitoring needed at dietary intake levels

Pharmacokinetic Profile